NADECNEMAB
UNII 1AIQ625714

Substance Identification & Data

This profile provides standardized clinical and technical data for Nadecnemab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 1AIQ625714.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2377679-19-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

1AIQ625714

CAS Registry Number

2377679-19-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

NADECNEMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C179104

National Cancer Institute reference terminology for clinical and research data.

INN ID

11567

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Nadecnemab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

NADECNEMAB

Common Names & Synonyms

IMMUNOGLOBULIN G4 (232-PROLINE), ANTI-(HUMAN GLIAL CELL-DERIVED NEUROTROPHIC FACTOR RECEPTOR .ALPHA.3) (HUMAN MONOCLONAL REGN5069 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN5069 .KAPPA.-CHAIN, DIMER

NADECNEMAB [INN]